乙型肝炎e抗原阴性慢性乙型肝炎患者停用核苷(酸)类似物治疗后乙型肝炎表面抗原清除的发生率及预测因素
在1075例乙型肝炎e抗原阴性且接受核苷(酸)类似物治疗的患者中,治疗期间乙型肝炎表面抗原清除年发生率估计为0.15%;691例按亚太肝病学会停药规则停药并前瞻性随访,停药后中位随访155周,42例确认乙型肝炎表面抗原清除,6年累积发生率为13%,估计年发生率为1.78%。
要点
- 治疗期间乙型肝炎表面抗原清除年发生率估计为0.15%,停药后估计年发生率为1.78%。
- 停药后6年乙型肝炎表面抗原清除累积发生率为13%。
- 临床复发未再治疗者乙型肝炎表面抗原清除发生率是接受再治疗者的7.34倍。
核心结论
- 停用核苷(酸)类似物后乙型肝炎表面抗原清除发生率远高于治疗期间,且在无病毒学和临床复发患者中最高。
- 出现临床复发而未治疗的患者乙型肝炎表面抗原清除发生率比接受再治疗者高7.34倍,提示短暂未治疗的临床复发可能驱动足够的免疫控制以达到功能性治愈。
研究设计与样本
- 共纳入1075例乙型肝炎e抗原阴性且接受核苷(酸)类似物治疗的患者,中位治疗156(61-430)周。
- 其中691例仍为乙型肝炎表面抗原阳性的患者按亚太肝病学会停药规则停药并前瞻性随访,年龄52.3岁,男性86%,肝硬化44.6%。
- 停药后中位随访155(2-614)周。
主要发现
- 1075例治疗期间5例出现乙型肝炎表面抗原清除,估计年发生率为0.15%。
- 691例停药患者中42例确认乙型肝炎表面抗原清除,6年累积发生率为13%,估计年发生率为1.78%。
- Cox回归分析显示,乙型肝炎病毒DNA不可测时间短(<12周)、治疗期间乙型肝炎表面抗原下降幅度大(>1 log10)、治疗结束时乙型肝炎表面抗原水平低(<100 IU/mL)、持续应答者以及未再治疗的复发者是停药后乙型肝炎表面抗原清除的因素。
- 临床复发未治疗者乙型肝炎表面抗原清除发生率是接受再治疗者的7.34倍。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Hepatitis B surface antigen (HBsAg) loss is a rare event during nucleos(t)ide analogue (Nuc) therapy. Limited data suggest that stopping Nuc therapy may increase HBsAg loss rate in hepatitis B e antigen-negative patients. A large study was conducted to investigate this issue in more detail. Of the 1,075 hepatitis B e antigen-negative patients treated with Nuc for a median of 156 (61-430) weeks, 5 showed HBsAg seroclearance during treatment at an estimated annual incidence of 0.15%. Of the patients who remained HBsAg-seropositive, 691 (52.3 years old, 86% male, 44.6% cirrhosis) had stopped Nuc therapy by the Asian-Pacific Association for the Study of the Liver stopping rule and then were prospectively followed up. Baseline and on-treatment clinical and viral features, treatment duration, consolidation duration, time to undetectable hepatitis B virus DNA, time to normal alanine aminotransferase, end-of-treatment HBsAg, and HBsAg log reduction were compared between patients with and without HBsAg seroclearance after end of treatment. During a median off-therapy follow-up period of 155 (2-614) weeks, HBsAg seroclearance was confirmed in 42 patients. The 6-year cumulative incidence was 13% with an estimated annual incidence of 1.78%. Cox regression analysis showed that shorter time to undetectable hepatitis B virus DNA (<12 weeks), greater HBsAg reduction during therapy (>1 log10 ), lower end-of-treatment HBsAg level (<100 IU/mL), patients with sustained response, and relapsers not retreated were factors for off-therapy HBsAg seroclearance. CONCLUSION: The incidence of HBsAg seroclearance after stopping Nuc was much higher than that during therapy and highest in patients without virologic and clinical relapse; patients with clinical relapse who remained untreated had a 7.34 times higher incidence of HBsAg clearance than those who received retreatment, suggesting that transient untreated clinical relapse may drive sufficient immune control to functional cure. (Hepatology 2017).
引用
- Jeng WJ, Chen YC, Chien RN, et al. Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 2018. PMID: 29108132. doi:10.1002/hep.29640
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。